Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark

BSE2049.7559.15 (+2.97 %)

PREV CLOSE ( ) 1990.60

OPEN PRICE ( ) 1990.60

BID PRICE (QTY) 2050.05 (37)

OFFER PRICE (QTY) 2051.85 (3)

VOLUME 15400

TODAY'S LOW / HIGH ( )1990.60 2055.15

52 WK LOW / HIGH ( )1274.7 2286.15

NSE2050.8059.9 (+3.01 %)

PREV CLOSE( ) 1990.90

OPEN PRICE ( ) 1990.90

BID PRICE (QTY) 2050.50 (41)

OFFER PRICE (QTY) 2050.80 (14)

VOLUME 717263

TODAY'S LOW / HIGH( ) 1990.90 2055.20

52 WK LOW / HIGH ( )1275.5 2284.8

Quarters

Select year

( in Million)

Particulars

Jun 2025

Mar 2025

Dec 2024

Sep 2024

Audited / UnAudited

UnAudited

Net Sales

32644.4

32562.06

33875.52

34337.96

Total Expenditure

26839.2

26951.81

27873.23

28318.84

PBIDT (Excl OI)

5805.2

5610.25

6002.29

6019.12

Other Income

264.42

116.85

311.28

394.17

Operating Profit

6069.62

5727.1

6313.57

6413.28

Interest

582.26

667.12

522.93

484.79

Exceptional Items

-3232.32

-3728.19

PBDT

2255.04

1331.79

5790.64

5928.49

Depreciation

1299.26

1252.05

1227.38

1202.78

Profit Before Tax

955.77

79.74

4563.26

4725.71

Tax

486.05

35.9

1082.95

1180.87

Provisions and contingencies

Profit After Tax

469.72

43.84

3480.31

3544.84

Extraordinary Items

Prior Period Expenses

Other Adjustments

Net Profit

469.72

43.84

3480.31

3544.84

Minority Interest

-1.02

2.66

-0.69

-2.71

Shares of Associates

Other related items

Misc. Expenses Written off

Consolidated Net Profit

468.71

46.5

3479.62

3542.14

Equity Capital

282.2

282.19

Face Value (IN RS)

Reserves

Calculated EPS

1.66

0.16

12.33

12.55

Calculated EPS (Annualised)

6.64

0.65

49.32

50.20

No of Public Share Holdings

150567872

150555219

150556969

% of Public Share Holdings

53.35

PBIDTM% (Excl OI)

17.78

17.22

17.71

17.52

PBIDTM%

18.59

17.58

18.63

18.67

PBDTM%

6.90

4.09

17.09

17.26

PBTM%

2.92

0.24

13.47

13.76

PATM%

1.43

0.13

10.27

10.32

Notes

Risk Disclosures on Derivatives

Quarterly Results

GLENMARK PHARMACEUTICALS LTD.